Skip to main content
. Author manuscript; available in PMC: 2022 Jan 14.
Published in final edited form as: J Card Fail. 2021 Jul 18;27(12):1447–1455. doi: 10.1016/j.cardfail.2021.07.003

Fig. 3.

Fig. 3.

Plasma renin activity with sodium-glucose cotransporter 2 (SGLT2) inhibition. (A) Increase in plasma renin activity by 117% after 1 week of bumetanide treatment in healthy volunteers (adapted from Wilcox et al. 201841; see Supplementary Fig. S6; available at: https://www.ahajournals.org/doi/10.1161/JAHA.117.007046; used under CC BY-NC 4.0; text slightly updated, parts of panels A and B combined, layout altered, and color added). (B) Week 12 change from baseline in plasma renin activity in patients with type 2 diabetes (T2D) treated with dapagliflozin (DAPA) or hydrochlorothiazide (HCTZ) (based on data from: Heerspink et al. 201343, Table 2). (C) Changes in plasma volume markers during DAPA treatment vs placebo treatment in patients with T2D (P < .01) (adapted from: Eickhoff et al 2019,50 Fig. 2, fourth panel from the left; available at: https://www.mdpi.com/2077-0383/8/6/779; used under CC BY 4.0; text slightly updated, layout altered, and color added).